Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine

Vaccination with Vaxfectin®adjuvanted SIV DNA induces long-lasting humoral immune responses able to reduce SIVmac251 Viremia

“…The Vaxfectin ® platform has been reported to enhance immunogenicity and effectiveness of several vaccine candidates. [34][35][36][37] Our data expand these reports and suggest Vaxfectin ® as a promising HIV DNA vaccine adjuvant.…”

“…33 Several studies have established that Vaxfectin ® adjuvanted DNA vaccines induce significantly higher antibody responses than DNAonly. [34][35][36][37] A preclinical evaluation of a prophylactic DNA vaccine adjuvanted with Vaxfectin ® against cytomegalovirus established that this vaccine platform was immunogenic and well-tolerated in mice and rabbits and showed a favorable safety profile. 38 A Vaxfectin ® adjuvanted HSV-2 DNA vaccine was shown to be effective in the guinea pig model of genital herpes for both prophylactic and therapeutic use.…”

“Current Dengue Vaccine Status”

“…The lipid-based adjuvant Vaxfectin (Vical incorporated) induced anti-dengue neutralizing antibodies against DENV-1, DENV-3, and DENV-4 in non-human primates. Shorter periods of viremia were seen in NHP vaccinated with the adjuvanted product after DENV 2 virus challenge [57]. A phase 1 human trial comparing the DNA tetravalent vaccine adjuvanted with two doses of vaxfectin administered at 0, 30, and 90 days has completed enrollment, and results are expected soon (NCT01502358).…”

Development of dengue vaccines

“…However, the average neutralization titres against each of the dengue serotypes were observed to vary greatly, being the highest against DENV-2 and lowest against DENV-4. 22 23 It was concluded that the rate of response appeared to be a dose-dependent trend.…”